Evaluating the Effects of Separate and Concomitant Use of MK-۲۲۰۶ and Salinomycin on Prostate Cancer Cell Line
- سال انتشار: 1401
- محل انتشار: مجله گزارش های بیوشیمی و زیست شناسی مولکولی، دوره: 11، شماره: 1
- کد COI اختصاصی: JR_RBMB-11-1_017
- زبان مقاله: انگلیسی
- تعداد مشاهده: 179
نویسندگان
Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
چکیده
Background: Prostate cancer is known as one of the most prevalent health disorders in the male population globally. The aim of the current study was to evaluate the effects of separate and concomitant use of MK-۲۲۰۶ and salinomycin on prostate cancer cell line. Methods: The antitumor potential of separate and concomitant use of MK-۲۲۰۶ and salinomycin was evaluated in a panel of prostate cancer cell line (PC-۳). To get insights into the underlying mechanism of action, different assays including the rate of apoptosis, cell viability, and gene expression were performed in treated prostate cancer cells. Results: A significant reduction was detected in the viability percentage of prostate cancer cells (p< ۰.۰۰۱) and the rate of Akt expression (p< ۰.۰۰۱) in all salinomycin, MK-۲۲۰۶, and salinomycin+MK-۲۲۰۶ groups compared to the negative control group. Furthermore, in comparison with the negative control group, there was a notable increase in both the rate of Bad expression (p< ۰.۰۰۱) and prostate cancer cells apoptosis after salinomycin, MK-۲۲۰۶, and salinomycin+MK-۲۲۰۶ treatments. Moreover, the concomitant use of salinomycin+MK-۲۲۰۶ revealed synergistic improvements regarding the viability of prostate cancer cells and the rate of the Akt and Bad expressions compared to the separate administration of salinomycin and MK-۲۲۰۶ (all p< ۰.۰۵). Conclusions: The findings of the present study may contribute to improving the efficacy of the therapies regarding the management of prostate cancer and providing a beneficial strategy in clinical trials.کلیدواژه ها
Apoptosis, Gene Expression, MK ۲۲۰۶, Prostatic Neoplasms, Salinomycin.اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.